Isis Pharmaceuticals
edit

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis’ broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. Isis’ partner, Genzyme, plans to commercialize Isis’ lead product, KYNAMRO™, in the United States and Europe following regulatory approval. Isis’ patents provide strong and extensive protection for its drugs and technology.

Recent Milestones
edit

Isis Pharmaceuticals — Isis Pharmaceuticals receives $6m payment from AstraZeneca PBR Staff Writer (6/10/13)

Posted 6/10/13 at 7:25pm via pharmaceutical-business-review.com
Isis Pharmaceuticals — Isis Pharmaceuticals, Inc. (ISIS) Receives $10 Million Milestone Payment (6/6/13)

Posted 6/6/13 at 10:34pm via biospace.com
Isis Pharmaceuticals — Isis earns $7.5M milestone on PhII/III trial launch (2/20/13)

Posted 2/20/13 at 8:13pm via fiercebiotech.com